Essar Steel case: The court stated that the NCLAT cannot interfere with the committee of creditors' commercial decisions

ArcelorMittal's South Africa says its Saldanha operations lost their competitive cost advantage to compete in the export market, \"mainly due to raw material and regulated prices\"

These are tricky times for Indian pharma and they can hardly afford any lapse in their production facilities when the US drug regulator (the US Food and Drug Administration) inspections happen.

Not all Indian bulk drug makers are reeling before the Chinese onslaught. Some have honed their processes to become world leaders in niche areas.

Azure Power CEO Inderpreet S. Wadhwa says from this advice, I have imbibed persistence, patience and resilience in both my personal and professional life.

Though they compete fiercely, Lupin Pharmaceuticals, Aurobindo Pharma, Zydus Cadila, Orchid Chemicals and Pharmaceuticals and Ranbaxy - each one a giant - came together in July 2010 to share their best practices, in a bid to improve efficiency and bring down rising operating costs.

Companies with revenues between Rs 1,000 crore and Rs 2,000 crore that grew the fastest in 2007.